Janus Henderson Group PLC Has $980.04 Million Holdings in Revolution Medicines, Inc. $RVMD

Janus Henderson Group PLC boosted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,303,502 shares of the company’s stock after purchasing an additional 947,448 shares during the quarter. Janus Henderson Group PLC owned 0.06% of Revolution Medicines worth $980,036,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Global Retirement Partners LLC raised its stake in Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after purchasing an additional 361 shares during the last quarter. Indiana Trust & Investment Management Co acquired a new position in shares of Revolution Medicines in the 4th quarter valued at $32,000. Torren Management LLC acquired a new position in shares of Revolution Medicines in the 4th quarter valued at $33,000. Arax Advisory Partners acquired a new position in shares of Revolution Medicines in the 4th quarter valued at $38,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Revolution Medicines in the 4th quarter valued at $40,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Stock Up 0.8%

RVMD opened at $157.77 on Thursday. The firm’s 50-day simple moving average is $144.38 and its 200-day simple moving average is $112.39. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.80 and a current ratio of 6.80. Revolution Medicines, Inc. has a twelve month low of $34.00 and a twelve month high of $166.50. The firm has a market cap of $33.54 billion, a price-to-earnings ratio of -22.32 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period last year, the company earned ($1.13) EPS. Equities research analysts anticipate that Revolution Medicines, Inc. will post -7.94 EPS for the current fiscal year.

Insider Activity

In other news, COO Margaret A. Horn sold 29,600 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $160.12, for a total value of $4,739,552.00. Following the sale, the chief operating officer owned 154,647 shares of the company’s stock, valued at approximately $24,762,077.64. This represents a 16.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark A. Goldsmith sold 120,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total transaction of $18,010,800.00. Following the completion of the sale, the insider directly owned 276,698 shares in the company, valued at approximately $41,529,602.82. The trade was a 30.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 210,000 shares of company stock worth $32,424,620. 7.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. UBS Group assumed coverage on shares of Revolution Medicines in a research note on Friday, February 27th. They issued a “buy” rating for the company. HC Wainwright increased their price objective on shares of Revolution Medicines from $169.00 to $195.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Oppenheimer increased their price objective on shares of Revolution Medicines from $165.00 to $195.00 and gave the company an “outperform” rating in a research note on Monday, June 1st. Wedbush restated an “outperform” rating on shares of Revolution Medicines in a research note on Monday, June 1st. Finally, Royal Bank Of Canada increased their price objective on shares of Revolution Medicines from $165.00 to $182.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $123.72.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.